Lemin Lab

current location： Home > Introduction

Lemin Zheng, Ph. D.

(Email: zhengl@bjmu.edu.cn; Tel: 010-82805452)

Vice Chair and professor of the Institute of Cardiovascular Sciences, Peking University; Member of the Party Committee, School of Basic Medical Sciences, Peking University; Distinguishied "Boya" Professor of Peking University; Assistant director of National Key Laboratory; Deputy Director, Cardio-Cerebrovascular and Metabolic Department, School of Basic Medical Sciences.

National "Ten thousand Talents Plan" scientific and technological innovation leading talents(2023); National "Ten Thousand Talents Plan" Youth Top Talents(2015); National "Excellent Youth Fund"(2014); Ministry of Education "New Century talents".

Director of Cardiometabolic and Proteomic Research (PI), Professor, doctoral supervisor, specializing in cardiovascular pathophysiology. After graduating from the Department of Chemistry, Beijing Normal University, he joined the Chinese Academy of Sciences. In 2000, he entered the Ph.D. program between Cleveland Clinic and Cleveland State University in clinical bioanalytical chemistry. Cleveland Clinic is one of the best hospitals in the United States. After graduating with his Ph.D., he worked in a biomedical company affiliated with Cleveland Clinic. In 2007, he entered the Institute of Cardiovascular Sciences (Peking University) as a PI and associate professor; in 2015, he was promoted to professor; in 2018, he served as Vice Chair and professor of the Institute of Cardiovascular Sciences; in 2024, he was appointed as the Distinguished "Boya" Professor of Peking University

He is currently a member of the Basic Science Group of the Cardiovascular Branch of the Chinese Medical Association, the deputy secretary-general of the Precision Medicine Branch of the Chinese Society of Cardiothoracic Anesthesiology, the leader of the Glycolipid Metabolism Group of the Vascular Branch of the Beijing Physiological Association, the member of the Cardiovascular Pharmacology Committee of the Chinese Pharmacological Society, and the member of Youth Committee of the Chinese Pathophysiology Association.

He obtained the “Excellent Young Scientists Fund” of the National Natural Science Foundation of China; the “Ten Thousand Talents Program” Youth Top Talent Fund of the Central Organization Department; and the “New Century Talent Fund” of the Ministry of Education. He also had over 7 National Natural Vessel Major Special Cultivation Funds, including 7 National Natural Funds, 2 Beijing General Funds, and many other funds, as a research keyman to participate in 4 major special projects of the Ministry of Science and Technology and “973” projects. He won the Chinese Medicine Award and the provincial and ministerial awards, the American Heart Association “Pre-doctoral Fellowship Award” and so on. A total of 135 SCI articles have been published, and 98 are the corresponding-author paper, which are cited 6690 times by SCI (h-index 39, Web of Science); Researchgate (https://www.researchgate.net/profile/Lemin-Zheng).

Major author articles (IF greater than 10: 27 articles; IF greater than 20: 9 articles) include:

1) Cardiovascular and cerebrovascular diseases:

European Heart Journal (IF=37.6, 2021); Neuron（14.7, 2023）；Nature Communications（IF=14.7, 2022）; Advanced Science（IF=14.3, 2023, 2022, 2021）; Cardiovascular Research（IF=10.2, 2021a, 2021b）; Signal transduction and targeted therapy（IF=40.8, 2023）; Science Bulletin（IF=18.8, 2023）; iMeta(IF=23.7, 2024, 2023) ; Stroke（2022, 2021）; Circulation: Heart Failure（2021）; European Heart Journal Open（2022）; Arteriosclerosis, Thrombosis, and Vascular Biology（2019）; Aging Cell（2018）; Redox Biology（IF=10.7, 2021,2018,2017）; Cell Death & Disease（2018).

2) Metabolic related diseases:

Signal transduction and targeted therapy（IF=40.8, 2024）；Gastroenterology（IF=25.7, 2020）; Cell Metabolism（IF=27.7, 2023）; Kidney International（IF=14.8, 2021）; Diabetes（2021）; Molecular Cancer（IF= 27.7, 2014）; Clinical Cancer Research（IF=10, 2012）.

3) Clinical translational research of cardiovascular and cerebrovascular diseases:

Advanced Materials （IF=27.4, 2020）; Advanced Functional Materials （IF=18.5, 2024, 2020, 2017）; Nano Letters（IF=9.6, 2021）; Biosensors and Bioelectronics（IF=10.7, 2022）；Nano Research（IF=9.5, 2020）.

In 2010, the invention patent passed the U.S. Patent Office and the European Patent Office, and a total of 4 Chinese patents were obtained in 2019, 2020, and 2021 (the first inventor). In 2014, he obtained a national CFDA cardiovascular clinical medical test kit, and in 2020, he obtained 9 clinical medical test kit from CFDA. His edited monograph HDL Metabolism and Diseases, was published by Springer Nature in May 2022.

He serves as an subeditor of Frontiers in Cardiovascular Medicine (IF=5.8) , an editorial board member of magazines such as Genes & Diseases (IF=7.2), Biology (IF=5.1), Cardiovascular Drugs and Therapy (IF=4.2), Cardiovascular & Hematological Disorders - Drug Targets, Lipid & Cardiovascular Research, Chinese Journal of Cardiovascular Research, Chinese Journal of Arteriosclerosis, and a reviewer for magazines such as Circulation, Nature Communication, Diabetologia, ACS Applied Materials & Interfaces, FASEB Journal, British Journal of Pharmacology, Free Radical Biology and Medicine, Cardiovascular Diabetology.

He is also a founding editor of the international magazine Global Translational Medicine (https://www.accscience.com/journal/GTM).

Research Interests

1. Study on the effects of metabolic pathways on cardiovascular and cerebrovascular homeostasis and disease mechanisms. Cardiac and vascular functional homeostasis is closely related to their metabolic states, and metabolic pathways are widely involved in the occurrence and development of cardiovascular and cerebrovascular diseases (such as aneurysms, myocardial infarction, stroke, etc.). Metabolic regulation is an important research field after gene regulation and protein regulation. The team identified a variety of metabolic molecules and pathways involved in new pathophysiological mechanisms of cardiovascular disease and key target proteins, including macrophages activating inflammatory responses through the release of succinic acid; Cell connexin Cx43 maintains vascular endothelial barrier function by regulating NAD+ levels. In aneurysmal state, smooth muscle cells GSDMD mediated the release of putressin and phenotypic transition. New mechanisms of lipid metabolism such as apo(a) and lipoprotein signaling pathways affecting the cardiovascular system.

2. Discovery of new active factors derived from endogenous and intestinal flora and their metabolic regulation. In cardiovascular and cerebrovascular disease-related population samples, we identified multiple active factors through multi-omics methods, and found their effects and mechanisms on metabolic related diseases such as diabetes, fatty liver, and tumors. Among them, we demonstrated that the endogenous factor membranin A1 acts on different cell types and plays a protective role in arterial dissection, diabetic nephropathy and obesity, and vascular endothelial metabolism regulates angiogenesis and tumor progression in tumors. Intestinal flora is another important source of human metabolism. The changes of metabolic spectrum caused by intestinal flora disturbance in the course of disease further affect the course of disease, thus generating new theoretical systems such as enteric axis, enteric brain axis and enteric liver axis. For the first time, the team identified a new metabolic product of intestinal flora, trimethylaminovaleric acid (TMAVA), and clarified its mechanism of aggravating fatty liver and heart hypertrophy. It also developed a mass spectrometry method for the detection of trimethylamine oxide (TMAO), an important metabolic product of intestinal flora activity, and discovered its new physiological functions in stroke and pulmonary hypertension. Through metabolic intervention and metabolism related regulation, we put forward new ideas and insights on the treatment of cardiovascular and cerebrovascular diseases and metabolic related diseases.

3. Combined with new materials and technologies to carry out translational medicine research on cardio-cerebrovascular related diagnosis and treatment. The application of new technologies to develop cardiovascular and cerebrovascular disease diagnosis and treatment methods, including the use of biological and nanomaterials equipped with imaging groups or pharmacological components to achieve non-invasive imaging or targeted therapy for diseases such as arterial plaque, the use of molecular probes and structural prediction to develop related drugs to correct disease metabolic disorders, the optimization of clinical mass spectrometry detection methods to develop a multi-indicator comprehensive warning system for cardiovascular and cerebrovascular diseases, etc. The diagnosis and treatment of cardiovascular and cerebrovascular diseases can continue to develop on the new track.

40 representative SCI papers (* as the lead author, the number of top 5% papers is 23) :

1. Lu Fang^#, Changjie Liu^#, Zong-Zhe Jiang, Mengxiao Wang, Kang Geng, Yangkai Xu, Yujie Zhu, Yiwen Fu, Jing Xue, Wenxin Shan, Qi Zhang, Jie Chen, Jiahong Chen, Mingming Zhao, Yuxuan Guo, K W Michael Siu, Y Eugene Chen, *Yong Xu, *Donghui Liu, *Lemin Zheng. Annexin A1 binds PDZ and LIM domain 7 to inhibit adipogenesis and prevent obesity. Signal transduction and targeted therapy. 2024 Aug 23;9(1):218. (IF=40.8，JCR：Q1)

2. Jiageng Cai^#, Xiaoxiao Ge^#, Shiyu Lu, Yabin Wang, Hongtu Cui, Rui Zhan, Sheng'e Su, Wenxin Shan, Zhulan Cai, Cencen Wu, Yuan Xu, Penghui Zhao, Yanyan Li, Yue Lan, Le Sun, *Shaojun Guo, *Lemin Zheng, *Lingyun Zu. Au/FeNiPO4-Based Multiple Spectra Optoacoustic Tomography/CT Dual-Mode Nanoprobe for Systemic Screening of Atherosclerotic Vulnerable Plaque. Advanced Functional Materials. 29 May 2024 https://doi.org/10.1002/adfm.202406192. (IF=18.5，JCR：Q1)

3. Yicheng Yang^#, Hanwen Zhang^#, Yaoyao Wang^#, Jing Xu^#, Songren Shu, Peizhi Wang , Shusi Ding, Yuan Huang, *Lemin Zheng, *Yuejin Yang, *Changming Xiong. Promising dawn in the management of pulmonary hypertension: The mystery veil of gut microbiota. iMeta. 2024 Jan 1;3(2):e159. (IF=23.7)

4. Jing Xu^#, Yicheng Yang^#, Xin Li^#, Shusi Ding, *Lemin Zheng, *Changming Xiong, *Yuejin Yang. Pleiotropic activities of succinate: The interplay between gut microbiota and cardiovascular diseases. iMeta. 2023 Jun 19;2(3):e124. (IF=23.7)

5. Rui Zhan^#, Xia Meng^#, Dongping Tian, Jie Xu, Hongtu Cui, Jialei Yang, Yangkai Xu, Mingming Shi, Jing Xue, Weiwei Yu, Gaofei Hu, Ke Li, Xiaoxiao Ge, Qi Zhang, Mingming Zhao, Jianyong Du, Xin Guo, Wenli Xu, Yang Gao, Changyu Yao, Fan Chen, Yue Chen, Wenxin Shan, Yujie Zhu, Liang Ji, Bing Pan, Yan Yu, Wenguang Li, Xuyang Zhao, Qihua He, Xiaohui Liu, Yue Huang, Shengyou Liao, Bin Zhou, Dehua Chui, Y Eugene Chen, Zheng Sun, *Erdan Dong, *Yongjun Wang, *Lemin Zheng. NAD+ rescues aging-induced blood-brain barrier damage via the CX43-PARP1 axis. Neuron. 2023 Aug 29:S0896-6273(23)00622-0. (IF=14.7，JCR：Q1)

6. Pengxiang Qu^#, Oren Rom^#, Ke Li^#, Linying Jia, Xiaojing Gao, Zhipeng Liu, Shusi Ding, Mingming Zhao, Huiqing Wang, Shuangshuang Chen, Xuelian Xiong, Ying Zhao, Chao Xue, Yang Zhao, Chengshuang Chu, Bo Wen, Alexandra C. Finney, Zuowen Zheng, Wenbin Cao, Jinpeng Zhao, Liang Bai, Sihai Zhao, Duxin Sun, Rong Zeng, Jiandie Lin, Wanqing Liu, *Lemin Zheng, *Jifeng Zhang, *Enqi Liu, Y. *Eugene Chen. DT-109 ameliorates nonalcoholic steatohepatitis in nonhuman primates. Cell Metabolism. 2023, April 10, ISSN 1550-4131. (IF=27.7，JCR：Q1)

7. Zekun Wang^#, Nana Yang^#, Yajun Hou, Yuqing Li, Chenyang Yin, Endong Yang, Huanhuan Cao, Gaofei Hu, Jing Xue, Jialei Yang, Ziyu Liao, Weiyun Wang, *Dongdong Sun, *Cundong Fan, *Lemin Zheng. L-Arginine-Loaded Gold Nanocages Ameliorate Myocardial Ischemia/Reperfusion Injury by Promoting Nitric Oxide Production and Maintaining Mitochondrial Function. Advanced science (Weinh). 2023 Sep;10(26):e2302123. (IF=14.3，JCR：Q1)

8. Jianing Gao^#, Huanhuan Cao, Gaofei Hu, Yufei Wu, Yangkai Xu, Hongtu Cui, Hong S Lu, *Lemin Zheng. The mechanism and therapy of aortic aneurysms. Signal transduction and targeted therapy. 2023 Feb 3;8(1):55. (IF=40.8，JCR：Q1)

9. Qingyuan Liu^#, Ke Li^#, Hongwei He, Zengli Miao, Hongtu Cui, Jun Wu, Shusi Ding, Zheng Wen, Jiyuan Chen, *Xiaojie Lu, *Jiangan Li, *Lemin Zheng, *Shuo Wang. The markers and risk stratification model of intracranial aneurysm instability in a large Chinese cohort. Science bulletin. 2023 May 10:S2095-9273(23)00308-0. (IF=18.8，JCR：Q1)

10. Jianing Gao^#, Yanghui Chen^#, Huiqing Wang, Xin Li, Ke Li, Yangkai Xu, Xianwei Xie, Yansong Guo, Nana Yang, Xinhua Zhang, Dong Ma, Hong S Lu, Ying H Shen, Yong Liu, Jifeng Zhang, Y Eugene Chen, Alan Daugherty, *Dao Wen Wang, *Lemin Zheng. Gasdermin D Deficiency in Vascular Smooth Muscle Cells Ameliorates Abdominal Aortic Aneurysm Through Reducing Putrescine Synthesis. Advanced Science (Weinh). 2022 Dec 25:e2204038. (IF=14.3，JCR：Q1)

11. Huanhuan Cao, Yujie Zhu, Gaofei Hu, Qi Zhang, *Lemin Zheng. Gut microbiome and metabolites, the future direction of diagnosis and treatment of atherosclerosis? Pharmacological Research. 2023 Jan;187:106586. (JCR：Q1)

12. Mingming Zhao^#, Haoran Wei^#, Chenze Li, Rui Zhan, Changjie Liu, Jianing Gao, Yaodong Yi, Xiao Cui, Wenxin Shan, Liang Ji, Bing Pan, Si Cheng, Moshi Song, Haipeng Sun, Huidi Jiang, Jun Cai, Minerva Garcia-Barrio, Y. Eugene Chen, Xiangbao Meng, Erdan Dong, *Dao Wen Wang, *Lemin Zheng. Gut microbiota production of trimethyl-5-aminovaleric acid reduces fatty acid oxidation and accelerates cardiac hypertrophy. Nature Communications. 2022 Apr 1;13(1):1757. (IF=14.7，JCR：Q1)

13. Yang Y^#, Zeng Q^#, Gao J^#, Yang B, Zhou J, Li K, Li L, Wang A, Li X, Liu Z, Luo Q, Zhao Z, Liu B, Xue J, Jiang X, Konerman MC, *Zheng Lemin, *Xiong C. High-circulating gut microbiota-dependent metabolite trimethylamine N-oxide is associated with poor prognosis in pulmonary arterial hypertension. European Heart Journal Open. 2022 Mar 29;2(5):oeac021.

14. Xu J^#, Hao X^#, Zhan R^#, Jiang X, Jin A, Xue J, Cheng A, Liu J, Lin J, Meng X, Li H, *Zheng L, *Wang Y. Effect of Lipoprotein(a) on Stroke Recurrence Attenuates at Low LDL-C (Low-Density Lipoprotein) and Inflammation Levels. Stroke. 2022 Apr 12:101161STROKEAHA121034924. (JCR：Q1)

15. Xiao-Xiao Chen^#, Yufei Wu^#, Xiaoxiao Ge, Liandi Lei, *Li-Ya Niu, *Qing-Zheng Yang, *Lemin Zheng. In vivo imaging of heart failure with preserved ejection fraction by simultaneous monitoring of cardiac nitric oxide and glutathione using a three-channel fluorescent probe. Biosensors and Bioelectronics. Volume 214, 2022, 114510, ISSN 0956-5663.（IF=10.7，JCR：Q1）

16. Cui H^#, Chen Y^#, Li K, Zhan R, Zhao M, Xu Y, Lin Z, Fu Y, He Q, Tang PC, Lei I, Zhang J, Li C, Sun Y, Zhang X, Horng T, Lu HS, Chen YE, Daugherty A, *Wang D, *Lemin Zheng. Untargeted metabolomics identifies succinate as a biomarker and therapeutic target in aortic aneurysm and dissection. European Heart Journal. 2021 Nov 7;42(42):4373-4385. (IF=37.6，JCR：Q1)

17. Jiang X, Xu J, Hao X, Xue J, Li K, Jin A, Lin J, Meng X, *Zheng L, *Wang Y. Elevated lipoprotein(a) and lipoprotein-associated phospholipase A2 are associated with unfavorable functional outcomes in patients with ischemic stroke. Journal of Neuroinflammation. 2021 Dec 28;18(1):307. (IF=9.3，JCR：Q1)

18. Xu J^#, Zhao M^#, Wang A, Xue J, Cheng S, Cheng A, Gao J, Zhang Q, Zhan R, Meng X, Xu M, Li H, Zheng L*, Wang Y*. Association Between Plasma Trimethyllysine and Prognosis of Patients With Ischemic Stroke. Journal of the American Heart Association. 2021 Dec 7;10(23):e020979. (JCR：Q1)

19. Xu J^#, Cheng A^#, Song B, Zhao M, Xue J, Wang A, Dai L, Jing J, Meng X, Li H, *Zheng L, *Wang Y. Trimethylamine N-Oxide and Stroke Recurrence Depends on Ischemic Stroke Subtypes. Stroke. 2021 Nov 19:STROKEAHA120031443. (JCR：Q1)

20. Li C^#, Zhao M^#, Xiao L, Wei H, Wen Z, Hu D, Yu B, Sun Y, Gao J, Shen X, Zhang Q, Cao H, Huang J, Huang W, Li K, Huang M, Ni L, Yu T, Ji L, Xu Y, Liu G, Konerman MC, *Lemin Zheng, *Wang D. Prognostic Value of Elevated Levels of Plasma N-Acetylneuraminic Acid in Patients With Heart Failure. Circulation: Heart Failure. 2021 Nov;14(11):e008459 （JCR：Q1）

21. Wu L^#, Liu C^#, Chang D Y, Zhan R, Zhao M, Lam S M, Shui G, Zhao M H, *Lemin Zheng, *Chen M. The attenuation of diabetic nephropathy by annexin A1 via regulation of lipid metabolism through AMPK/PPARα/CPT1b pathway. Diabetes. 2021 Oct;70(10):2192-2203. (JCR：Q1)

22. Zhou C, Lin Z, Cao H, Chen Y, Li J, Zhuang X, Ma D, Ji L, Li W, Xu S, *Pan B, *Lemin Zheng. Anxa1 in smooth muscle cells protects against acute aortic dissection. Cardiovascular Research. 2021 Mar 23:cvab109. (IF=10.2，JCR：Q1)

23. Jingxuan Li^#, Yingyu Chen^#, Jianing Gao, Yue Chen, Changping Zhou, Xin Lin, Changjie Liu, Mingming Zhao, Yangkai Xu, Liang Ji, Zongzhe Jiang, *Bing Pan, *Lemin Zheng. Eva1a ameliorates atherosclerosis by promoting re-endothelialization of injured arteries via Rac1/Cdc42/Arpc1b. Cardiovascular Research. 2021 Jan 21;117(2):450-461. (IF=10.2，JCR：Q1)

24. Man Z, Cui H, Lv Z, Xu Z*, Wu Z, Wu Y, Liao Q, Liu M, Xi P*, Zheng L*, Fu H*. Organic Nanoparticles-Assisted Low-Power STED Nanoscopy. Nano Letters. 2021 Apr 28;21(8):3487-3494. (IF=9.6，JCR：Q1)

25. Wu L^#, Liu C^#, Chang DY, Zhan R, Sun J, Cui SH, Eddy S, Nair V, Tanner E, Brosius FC, Looker HC, Nelson RG, Kretzler M, Wang JC, Xu M, Ju W, Zhao MH, *Chen M, *Lemin Zheng. Annexin A1 alleviates kidney injury by promoting the resolution of inflammation in diabetic nephropathy. Kidney International. 2021 Jul;100(1):107-121. (IF=14.8，JCR：Q1)

26. Zhang M^#, Gao J^#, Zhao X, Zhao M, Ma D, Zhang X, Tian D, Pan B, Yan X, Wu J, Meng X, Yin H, *Lemin Zheng. p38α in macrophages aggravates arterial endothelium injury by releasing IL-6 through phosphorylating megakaryocytic leukemia 1. Redox Biology. 2021 Jan;38:101775. (IF=10.7，JCR：Q1)

27. Jian Kong^#, Changyu Yao^#, Shuying Dong^#, Shilun Wu, Yangkai Xu, Ke Li, Liang Ji, Qiang Shen, Qi Zhang, Rui Zhan, Hongtu Cui, Changping Zhou, Haigang Niu, Guoming Li, *Wenbing Sun, *Lemin Zheng. ICAM-1 Activates Platelets and Promotes Endothelial Permeability through VE-cadherin after Insufficient Radiofrequency Ablation. Advanced Science (Weinh). 2021 Jan 4;8(4):2002228. (IF=14.3，JCR：Q1)

28. Mingming Zhao^#, Lin Zhao^#, Xuelian Xiong, Yuan He, Wei Huang, Zihao Liu, Liang Ji, Bing Pan, Xuefeng Guo, Leibo Wang, Si Cheng, Ming Xu, Hongyuan Yang, Yuxin Yin, Minerva T. Garcia-Barrio, Y. Eugene Chen, Xiangbao Meng, *Lemin Zheng. TMAVA, a Metabolite of Intestinal Microbes, Is Increased in Plasma From Patients With Liver Steatosis, Inhibits γ-butyrobetaine Hydroxylase, and Exacerbates Fatty Liver in Mice. Gastroenterology. 2020 Jun;158(8):2266-2281. (IF=25.7，JCR：Q1)

29. Xiaoxiao Ge^#, Hongtu Cui^#, Jian Kong, Shi-Yu Lu, Rui Zhan, Jianing Gao, Yangkai Xu, Shuangyan Lin, Kaixin Meng, Lingyun Zu, Shaojun Guo, *Lemin Zheng. A Non-Invasive Nanoprobe for In Vivo Photoacoustic Imaging of Vulnerable Atherosclerotic Plaque. Advanced Materials. 2020 Sep;32(38):e2000037. (IF=27.4，JCR：Q1)

30. Zheng Lv^#, Zhongwei Man^#, Hongtu Cui, Zhenzhen Xu*, Huanhuan Cao, Shuai Li, Qing Liao, Qihua He, Lemin Zheng*, and Hongbing Fu*. Red AIE Luminogens with Tunable Organelle Specific Anchoring for Live Cell Dynamic Super Resolution Imaging. Advanced Functional Materials. 2020, 31(10), 2009329. (IF=18.5，JCR：Q1)

31. Zheng Lv ^#, Li Li^#, Zhongwei Man, Zhenzhen Xu*, Hongtu Cui, Rui Zhan, Qihua He, *Lemin Zheng, Hongbing Fu*. Polarity-activated super-resolution imaging probe for the formation and morphology of amyloid fibrils. Nano Research. 2020, 13(9): 2556-2563. (IF=9.5，JCR：Q1)

32. Jianping Li^#, Changping Zhou^#, Hongbing Xu^#, Robert Brook, Shengcong Liu, Tieci Yi, Yang Wang, Baihuan Feng, Mingming Zhao, Xu Wang, Qian Zhao, Jie Chen, Xiaoming Song, Tong Wang, Shuo Liu, Yi Zhang, Rongshan Wu, Jianing Gao, Bing Pan, Subramaniam Pennathur, Sanjay Rajagopalan, Yong Huo, *Lemin Zheng, *Wei Huang. Ambient Air Pollution is Associated with High-Density Lipoprotein Dysfunction in Healthy Adults. Arteriosclerosis, Thrombosis, and Vascular Biology. 2019 Mar;39(3):513-522. （JCR：Q1）

33. Ke Y#, Li D#, Zhao M, Liu C, Liu J, Zeng A, Shi X, Cheng S, Pan B, *Lemin Zheng, *Hong H. Gut flora-dependent metabolite Trimethylamine-N-oxide accelerates endothelial cell senescence and vascular aging through oxidative stress. Free Radical Biology and Medicine. 2018 Jan 8;116:88-100. (JCR：Q2)

34. He D^#, Zhao M^#, Wu C, Zhang W, Niu C, Yu B, Jin J, Ji L, Willard B, Mathew A, Chen Y, Pennathur S, Yin H, He Y, *Pan B, *Lemin Zheng. Apolipoprotein A-1 mimetic peptide 4F promotes endothelial repairing and compromises reendothelialization impaired by oxidized HDL through SR-B1. Redox Biology. 2018 May;15:228-242. (IF=10.7，JCR：Q1)

35. Zhan R, Zhao M, Zhou T, Chen Y, Yu W, Zhao L, Zhang T, Wang H, Yang H, Jin Y, He Q, Yang X, Guo X, Willard B, Pan B, Huang Y, Chen Y, *Chui D, *Lemin Zheng. Dapsone protects brain microvascular integrity from high-fat diet induced LDL oxidation. Cell Death & Disease. 2018 Jun 7;9(6):683. （JCR：Q1）

36. Li D^#, Ke Y^#, Zhan R, Liu C, Zhao M, Zeng A, Shi X, Ji L, Cheng S, Pan B, *Lemin Zheng, *Hong H. Trimethylamine-N-oxide promotes brain aging and cognitive impairment in mice. Aging Cell. 2018 Aug;17(4):e12768. (JCR：Q1)

37. Lu J^#, Chen B^#, Chen T, Guo S, Xue X, Chen Q, Zhao M, Xia L, Zhu Z, *Lemin Zheng, *Yin H. Comprehensive metabolomics identified lipid peroxidation as a prominent feature in human plasma of patients with coronary heart diseases. Redox Biology. 2017 Aug;12:899-907. (IF=10.7，JCR：Q1)

38. Feng C, *Xu Z, Wang X, Yang H, *Lemin Zheng, *Fu H. Organic-nanowire-SiO2 core-shell microlasers with highly polarized and narrow emissions for biological imaging. ACS Applied Materials & Interfaces. 2017.Mar 1;9(8):7385-7391. (JCR：Q2)

39. Zhang H, Wang X, Liao Q, Xu Z, Li H, *Lemin Zheng, *Fu H. Embedding Perovskite Nanocrystals into a Polymer Matrix for Tunable Luminescence Probes in Cell Imaging. Advanced Functional Materials. 2017 Feb;27(7):1604382. (IF=18.5，JCR：Q1)

40. Kong J, Kong F, Gao J, Zhang Q, Dong S, Gu F, Ke S, Pan B, Shen Q, Sun H, *Lemin Zheng, Sun W*, YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma. Molecular Cancer. 2014 Jan 13;13:7. (IF=27.7，JCR：Q1)